Prot #221611: A Phase 3b, Open Label, Randomized, Standard-Of-Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living with HIV-1 (CROWN)

Project: Research project

Project Details

StatusActive
Effective start/end date11/7/24 → 11/7/27

Funding

  • PPD Investigator Services, LLC (Prot #221611 // Prot #221611)
  • GlaxoSmithKline LLC (Prot #221611 // Prot #221611)